ArticleEmerging infectious diseases2023
Emergence of Erythromycin-Resistant Invasive Group A Streptococcus, West Virginia, USA, 2020-2021.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Inhibitors of GapN-dependent NADPH supply as potential lead compounds for novel therapeutics againstVirulence · 2026Article
- Burden of invasive group a streptococcus infection in Australia: a systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- The Complexity of erm-Mediated Resistance: Structural and Functional Perspectives From β-Hemolytic Streptococci.Molecular microbiology · 2026Review
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.npj antimicrobials and resistance · 2026Article
- Machine learning-based discovery of GW3965 as a therapeutic compound against invasive emm92-type group A Streptococcus.Research square · 2026Article
- Case report: Necrotizing fasciitis involving the bilateral scrotum and right leg caused by Streptococcus pyogenes in a healthy male: a multidisciplinary diagnostic and therapeutic analysis.BMC infectious diseases · 2026Article
- The Impact of Penicillin Allergy on Infection Rates in Tissue Expander Breast Reconstruction: A 7-year Analysis.Plastic and reconstructive surgery. Global open · 2026Article
- Molecular epidemiology and antimicrobial susceptibility of group A Streptococcus isolated from children in Greece during 2023.Infection · 2026Article
- Transcriptome of macrolide-resistantMicrobiology resource announcements · 2025Article
- Choosing Wisely: Effectiveness and Safety of Antibiotic Prophylaxis in Close Contacts of Invasive Group A Streptococci Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Genomic interrogation of invasive group AThe Lancet regional health. Western Pacific · 2025Article
- Insights into MLSJAC-antimicrobial resistance · 2025Article
- Regulation of erm(T) MLSnpj antimicrobials and resistance · 2024Article
- Tracking progress on antimicrobial resistance by the quadripartite country self-assessment survey (TrACSS) in G7 countries, 2017-2023: opportunities and gaps.Pharmacological research · 2024Review
- Antibiotic Use for Common Infections in Pediatric Emergency Departments: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clindamycin and β-lactam antibiotics have been mainstays for treating invasive group A Streptococcus (iGAS) infection, yet such regimens might be limited for strains displaying MLS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.